US v. Holmes: Theranos Fraud Verdict, Sentence & Appeal

In the Elizabeth Holmes Theranos fraud case, a federal jury in January 2022 convicted the company’s founder on four counts of wire fraud against investors, U.S. District Judge Edward Davila sentenced her to 135 months in federal prison and ordered $452 million in restitution, and the Ninth Circuit Court of Appeals affirmed the conviction, sentence, and restitution order on February 24, 2025.¹

The Federal Charges

A federal grand jury in the Northern District of California first indicted Holmes and former Theranos president Ramesh “Sunny” Balwani in June 2018. Prosecutors superseded the indictment twice in July 2020. The final version charged each defendant with two counts of conspiracy to commit wire fraud under 18 U.S.C. § 1349 and nine counts of substantive wire fraud under 18 U.S.C. § 1343, for a total of eleven counts each.²

The government framed the case around two schemes. One targeted investors, alleging that Holmes and Balwani made false and misleading statements about Theranos’s technology, business performance, and financial condition to raise hundreds of millions of dollars. The other targeted patients, alleging the pair deceived doctors and patients about the accuracy and reliability of the company’s Edison blood-testing device.²

Each wire fraud count under § 1343 carries a maximum of 20 years in federal prison, and the conspiracy statute carries the same maximum as the underlying offense.³⁴

The Split Verdict

After roughly seven days of deliberations, the jury returned a mixed result in January 2022. Holmes was found guilty on one count of conspiracy to defraud investors and three counts of substantive wire fraud tied to specific transfers of investor money totaling more than $144 million. She was acquitted on all four patient-related counts. The jury deadlocked on three remaining investor counts, and Judge Davila declared a mistrial on those.¹

The patient acquittals turned on intent. At least one juror later explained publicly that while the panel believed Theranos’s laboratory was poorly run, the evidence did not show Holmes had deliberately set out to sell flawed tests to patients. Sloppy operations are not the same as intentional fraud, and the jury concluded prosecutors had not closed that gap.

The investor counts were different. Prosecutors put in evidence that Holmes had sent Walgreens a validation report bearing the Pfizer logo even though Pfizer had never validated the technology. On the stand, Holmes admitted placing the logo there. Jurors also heard that Holmes told investors Theranos technology had been deployed by the U.S. Department of Defense on the battlefield in Afghanistan and on medevac helicopters, and that the company projected more than $100 million in 2014 revenue. Neither claim held up: the military never deployed the device, and Theranos generated only about $100,000 in revenue from operations that year.⁵

Prison Sentence and Restitution

Judge Davila sentenced Holmes in November 2022 to 135 months, or 11 years and 3 months, followed by three years of supervised release. That figure sits at the bottom of the guidelines range the court calculated. The court found the offense caused $120 million in loss to investors and involved ten or more victims, producing a guidelines range of 135 to 168 months.¹

In May 2023, Judge Davila ordered Holmes to pay $452 million in restitution, holding her jointly and severally liable with Balwani. That total breaks down to $397 million owed to twelve identified investor victims and $54.5 million owed to Safeway and Walgreens, the retail partners that invested in the Theranos rollout.¹

Joint and several liability means each defendant is individually responsible for the full $452 million regardless of what either one personally received from the fraud. Victims can pursue Holmes or Balwani for the entire amount. Once the total collected from both defendants reaches $452 million, the obligation is satisfied for both. The court does not allocate restitution by role or by personal gain.

Balwani’s Parallel Case

Holmes and Balwani were tried separately, and Balwani fared worse. His trial ran in mid-2022, and the jury convicted him on all twelve counts he faced: ten counts of wire fraud and two counts of conspiracy. Unlike Holmes, he was found guilty on both the investor and the patient charges.¹

His guidelines range came out the same as Holmes’s, 135 to 168 months, based on identical loss and victim findings. Judge Davila sentenced him to 155 months, or 12 years and 11 months, and imposed the same $452 million restitution obligation on a joint and several basis. Balwani began serving his sentence in April 2023 at Federal Correctional Institution Lompoc II in California.¹

The Ninth Circuit Appeal

Both defendants appealed their convictions, sentences, and the restitution order. On February 24, 2025, a three-judge Ninth Circuit panel affirmed on every point for both Holmes and Balwani.¹

Among the sentencing arguments, the defendants challenged the district court’s calculation of financial loss and the standard of proof used to make that finding. The Ninth Circuit upheld the district court’s use of the preponderance-of-the-evidence standard, which is the ordinary standard for sentencing findings in federal court and a lower bar than the beyond-a-reasonable-doubt standard that governs at trial. The panel found no error in the $120 million loss figure that drove the guidelines calculation.¹

With the February 2025 ruling, neither Holmes nor Balwani has any remaining appeal as of right, though either could seek review from the U.S. Supreme Court.

The Separate SEC Civil Case

The criminal case ran alongside a civil action brought by the Securities and Exchange Commission in March 2018. The SEC alleged Holmes, Balwani, and Theranos raised more than $700 million from investors through false and misleading statements about the company’s technology and finances.⁵

Holmes settled that case without admitting or denying the allegations. She agreed to pay a $500,000 penalty, return 18.9 million shares of Theranos stock, give up her super-majority voting control of the company, and accept a ten-year bar from serving as an officer or director of any public company.⁶ The SEC settlement is a separate matter from the criminal restitution order and does not reduce it.

Where Holmes Is Now

Holmes reported to Federal Prison Camp Bryan, a minimum-security women’s facility in Bryan, Texas, on May 30, 2023, after a federal judge denied her request to remain free on bail while her appeal was pending. Her projected release date, accounting for potential good time credits, is approximately late 2031.

Under the First Step Act, federal inmates can earn up to 54 days of good time credit for each year of their imposed sentence, which meaningfully reduces the time actually served. For a sentence of Holmes’s length, full good time credits could shave roughly two years off the 135-month term.⁷

1
United States Court of Appeals for the Ninth Circuit. United States v. Holmes, No. 22-10312
2
United States Department of Justice. U.S. v. Elizabeth Holmes, et al.
3
Office of the Law Revision Counsel. 18 USC 1343 – Fraud by Wire, Radio, or Television
4
Office of the Law Revision Counsel. 18 USC 1349 – Attempt and Conspiracy
5
Securities and Exchange Commission. Theranos, CEO Holmes, and Former President Balwani Charged With Massive Fraud
6
Securities and Exchange Commission. Elizabeth Holmes, et al. and Ramesh Sunny Balwani
7
Federal Bureau of Prisons. An Overview of the First Step Act